Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

NetworkNewsWire Editorial Coverage

NEW YORK, July 9, 2025 /CNW/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades (https://ibn.fm/dyQrw). By 2050, the American Cancer Society estimates that annual cancer diagnoses will reach 35 million. While advances in treatment have improved outcomes for some patients, the demand for more effective therapies remains urgent — and the opportunity for innovation and market impact is significant. Calidi Biotherapeutics Inc. (NYSEAmerican:CLDI) (Profile) is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors. Using engineered viruses to transport therapeutic payloads with precision, Calidi's technology aims to transform the landscape of cancer treatment. Though oncology is its initial focus, the company is also exploring broader applications in high-need areas such as autoimmune disorders. In doing so, Calidi is positioning itself among a select group of biotech innovators, including Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), ImmunityBio Inc. (NASDAQ:IBRX), Crispr Therapeutics AG (NASDAQ:CRSP) and CytomX Therapeutics Inc. (NASDAQ:CTMX).